BOULDER, Colo., Dec. 8, 2016 /PRNewswire/ -- Venaxis®, Inc.
(Nasdaq: APPY), announced that following the approval from
shareholders at the 2016 Annual Meeting of Shareholders of the
proposal to change the Company's name, the Company's name has been
changed to Bioptix, Inc and the trading symbol for its Common
Shares will change to "BIOP" effective at the opening of trading on
December 12, 2016. The Company's
Common Stock trades on the NASDAQ Capital Market and the new CUSIP
is 09074N101.
"Changing the company's name and trading symbol reflects our
current business focus following the September 12, 2016 acquisition of BiOptix
Diagnostics, Inc.," said Steve
Lundy, Chief Executive Officer of Bioptix, Inc.
About Bioptix, Inc.--
Bioptix, Inc., through its operating subsidiary BiOptix
Diagnostics, Inc., has developed an Enhanced Surface Plasmon
Resonance ("SPR") instrument designed to increase the flexibility
and reliability of SPR, in order to address the increasing demand
for instruments suitable for a broader range of applications, while
offering far greater performance per dollar than other instruments
commercially available. BiOptix SPR biosensors shed light on
important binding parameters that are crucial for determining
whether a biologic or small molecule drug will be efficacious in
humans and at what dose a drug should be administered.
Contact: InvestorRelations@venaxis.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/venaxis-reports-name-change-to-bioptix-inc-and-nasdaq-ticker-symbol-change-to-biop-from-appy-300375522.html
SOURCE Venaxis, Inc.